260 related articles for article (PubMed ID: 24006273)
21. The dilemmas of prostate cancer screening.
Miklos GG
Med J Aust; 2013 Nov; 199(9):582. PubMed ID: 24182213
[No Abstract] [Full Text] [Related]
22. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
[No Abstract] [Full Text] [Related]
23. US guideline may have led to drop in PSA testing among primary care physicians, studies find.
McCarthy M
BMJ; 2015 May; 350():h2906. PubMed ID: 26021822
[No Abstract] [Full Text] [Related]
24. Prostate cancer risk calculators using ERSPC-derived data underestimate the risk if the WHO IRP 96/670 standard is used in prostate-specific antigen analysis.
Tormey WP
Eur Urol; 2015 Sep; 68(3):541-2. PubMed ID: 25819721
[No Abstract] [Full Text] [Related]
25. A Pragmatic Approach to Prostate Cancer Screening.
Tosoian JJ; Penson DF; Chinnaiyan AM
JAMA; 2024 May; 331(17):1448-1450. PubMed ID: 38581253
[No Abstract] [Full Text] [Related]
26. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
McKenzie PR; Delahunt B; Kench JG; Sikaris KA
Pathology; 2014 Jan; 46(1):91-2. PubMed ID: 24300730
[No Abstract] [Full Text] [Related]
27. 5-Alpha reductase inhibitors and PSA screening for prostate cancer.
Zardawi IM
Pathology; 2014 Jan; 46(1):91. PubMed ID: 24300722
[No Abstract] [Full Text] [Related]
28. Toward a smarter prostate cancer screening program.
Sjoberg DD
Eur Urol; 2015 Oct; 68(4):598-9. PubMed ID: 24836056
[No Abstract] [Full Text] [Related]
29. What is a "Diagnostic Test Reference Range" Good for?
Habibzadeh P; Yadollahie M; Habibzadeh F
Eur Urol; 2017 Nov; 72(5):859-860. PubMed ID: 28558944
[No Abstract] [Full Text] [Related]
30. Risk-based prostate cancer screening: who and how?
Glass AS; Cary KC; Cooperberg MR
Curr Urol Rep; 2013 Jun; 14(3):192-8. PubMed ID: 23532499
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
[TBL] [Abstract][Full Text] [Related]
32. Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed.
Carter HB
Oncology (Williston Park); 2014 Feb; 28(2):155-6. PubMed ID: 24701706
[No Abstract] [Full Text] [Related]
33. Prostate cancer: Rescreening policies and risk calculators.
Roobol MJ
Nat Rev Urol; 2014 Aug; 11(8):429-30. PubMed ID: 24980199
[No Abstract] [Full Text] [Related]
34. Improving outcomes for New Zealand men with prostate cancer.
Nacey JN; Delahunt B; Mark SD
N Z Med J; 2014 Feb; 127(1389):13-6. PubMed ID: 24548952
[No Abstract] [Full Text] [Related]
35. Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
Hu JC; Nanus DM; Sedrakyan A
Eur Urol; 2017 Jan; 71(1):147-149. PubMed ID: 27402061
[No Abstract] [Full Text] [Related]
36. Re: The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-Specific Antigen Levels: A Meta-Analysis.
Siegel C
J Urol; 2015 Aug; 194(2):395. PubMed ID: 26195367
[No Abstract] [Full Text] [Related]
37. Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.
Mittakanti HR; Thomas IC; Shelton JB; Makarov DV; Skolarus TA; Cooperberg MR; Chung BI; Sonn GA; Brooks JD; Leppert JT
J Clin Oncol; 2016 Oct; 34(29):3586-3587. PubMed ID: 27458297
[No Abstract] [Full Text] [Related]
38. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
39. [Cancer screening in Japan and prostate cancer screening].
Kakizoe T
Gan To Kagaku Ryoho; 2014 May; 41(5):539-44. PubMed ID: 24917000
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
Jackson BR
Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
